反应原性的阴影:既往疫苗体验引发的家长犹豫
本文通过针对性文献综述,探讨家长或照护者既往经历疫苗反应原性后对儿童接种犹豫的影响。综述显示,即便轻微或预期的不良事件也可引发情绪回避、高估未来反应风险、削弱信任并增加受反疫苗言论影响的风险,这些体验常超过临床证据影响接种决策。作者建议医护人员进行共情透明沟通、提供低反应原性疫苗选项并早期优化疫苗配方。
要点
- 家长或照护者既往经历疫苗反应原性可引发并长期维持接种犹豫。
- 轻微或预期不良事件即可触发焦虑、高估风险并削弱对疫苗安全的信任。
- 共情透明沟通与提供低反应原性疫苗选项可能有助于缓解家长顾虑。
核心结论
- 家长或照护者既往经历疫苗反应原性与后续儿童接种犹豫之间存在一致关联。
- 这些体验常超过临床证据影响疫苗决策并导致长期犹豫。
- 应对家长疫苗犹豫需要多层面策略,包括沟通、疫苗选项与配方优化。
研究设计与样本
- 针对性文献综述,纳入关于家长或照护者既往疫苗反应原性体验与接种犹豫关联的研究。
主要发现
- 轻微或预期的不良事件 following immunization(AEFIs)可触发情绪回避或焦虑。
- 既往反应体验可导致家长高估未来反应的可能性与严重程度。
- 既往反应体验可削弱对医疗系统和疫苗安全信息的信任。
- 既往反应体验可使家长更易受反疫苗言论影响,尤其当反应发生于家长或其子女时。
- 这些体验常超过临床证据影响疫苗决策并导致长期犹豫。
临床怎么用
- 医护人员应进行共情、透明的沟通,提供关于预期副作用的清晰信息。
- 医护人员应说明不同疫苗平台之间的差异。
- 在可行时提供反应原性较低的疫苗选项以缓解顾虑。
- 在早期开发阶段主动优化疫苗配方以降低反应原性,可能减少下游犹豫。
- 公共卫生策略应承认家长疫苗犹豫的情感与体验维度以支持知情决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccination has dramatically reduced the global burden of pediatric vaccine-preventable diseases, yet a decline in immunization rates in recent years has led to the re-emergence of diseases once nearing eradication, such as measles and pertussis. This trend is of particular concern for children with chronic conditions or those who are immunocompromised, as they face elevated risks of severe illness and complications. Parental vaccine hesitancy (PVH) plays a central role in this decline and is a multifactorial phenomenon shaped by demographic and socioeconomic factors, the child's health condition, parental attitudes and personal experiences, perceived disease risk and trust in the government and healthcare system. This targeted literature review demonstrates a consistent association between prior experiences of vaccine reactogenicity among parents or caregivers and subsequent hesitancy to vaccinate their children. Even mild or anticipated adverse events following immunization (AEFIs) can trigger emotional aversion or anxiety, lead to overestimation of the likelihood and severity of future reactions, erode trust in the healthcare system and vaccine safety information, and open susceptibility to anti-vaccine rhetoric, particularly when experienced by parents or their children. These experiences often outweigh clinical evidence in shaping vaccine decisions and contribute to long-term hesitancy. Addressing PVH requires a multifaceted approach. Healthcare providers must engage in empathetic, transparent communication, offering clear information about expected side effects and differences in vaccine platforms. Where feasible, offering less reactogenic vaccine options may help mitigate concerns. Additionally, proactively optimizing vaccine formulations for low reactogenicity in early development could reduce downstream hesitancy and improve public confidence. By acknowledging the emotional and experiential dimensions of PVH, public health strategies can better support informed parental decision-making and improve vaccine uptake in vulnerable pediatric populations.
引用
- Gschwend MH, Faust E, Rousculp MD, et al. The shadow of reactogenicity: Parental hesitancy due to prior vaccine experiences. Vaccine. 2025. PMID: 41412016. doi:10.1016/j.vaccine.2025.128120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。